We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Blood Test-Based Method Diagnoses Bile Acid Diarrhea from Single Sample

By LabMedica International staff writers
Posted on 07 Jul 2023
Print article
Image: A new method makes it easier to identify the right treatment for bile acid diarrhea (Photo courtesy of Freepik)
Image: A new method makes it easier to identify the right treatment for bile acid diarrhea (Photo courtesy of Freepik)

Bile acid malabsorption, also known as bile acid diarrhea, is a type of chronic diarrhea characterized by more than ten sudden episodes of diarrhea in a day. While the condition isn't life-threatening, it can severely disrupt a patient's day-to-day life, particularly their social activities, and can be significantly debilitating. Often, most instances of bile acid diarrhea are either diagnosed at an advanced stage or go undetected entirely, resulting in patients enduring this condition for several years before receiving a diagnosis. Now, a new study has discovered innovative methods for diagnosing bile acid diarrhea and identifying the most effective treatment tailored for each patient.

A team of researchers at University of Copenhagen (Copenhagen, Denmark) has devised a new approach for diagnosing bile acid diarrhea using a simple blood sample. This new technique focuses on blood molecules referred to as metabolites. A blood sample comprises several distinct metabolites. Among the nearly 1,300 identified metabolites, about a handful can be utilized to diagnose bile acid diarrhea. The metabolites in bile acid diarrhea patients form a specific pattern, making them easily identifiable.

For their research, the team examined blood samples from 50 patients and quickly observed that the samples – and by extension, the patients – could be segregated into two groups. Following this, the patients participated in a randomized clinical study where the researchers explored the effects of two different treatments: the standard treatment with bile acid sequestrant colesevelam and a novel treatment with liraglutide, typically used to manage type 2 diabetes and severe obesity. The clinical study revealed that while colesevelam treatment alleviated the bile acid diarrhea symptoms in 50% of the patients, liraglutide treatment proved successful for 77% of the patients.

“What is interesting is that the metabolites in the patients’ blood divided them into two groups: one that responds well to colesevelam and one that responds well to liraglutide. This suggests that we should be able to say which treatment is the most effective by analyzing the patient’s blood at the time of diagnosis,” said Professor Jesper Bøje Andersen from the Biotech Research & Innovation Centre.

Related Links:
University of Copenhagen 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.